Showing posts with label Hepatitis B Vaccination. Show all posts
Showing posts with label Hepatitis B Vaccination. Show all posts

Friday, March 25, 2016

An Economic Evaluation of Contingency Management for Completion of Hepatitis B Vaccination in Those on Treatment for Opiate Dependence

AIMS:
To determine whether the provision of contingency management using financial incentives to improve hepatitis B vaccine completion in people who inject drugs entering community treatment represents a cost-effective use of healthcare resources.

DESIGN:
A probabilistic cost-effectiveness analysis was conducted, using a decision-tree to estimate the short-term clinical and healthcare cost impact of the vaccination strategies, followed by a Markov process to evaluate the long-term clinical consequences and costs associated with hepatitis B infection.

SETTINGS AND PARTICIPANTS:
Data on attendance to vaccination from a UK cluster randomised trial.

INTERVENTION:
Two contingency management options were examined in the trial: fixed vs. escalating schedule financial incentives.

MEASUREMENT:
Lifetime healthcare costs and quality-adjusted life years discounted at 3.5% annually; incremental cost-effectiveness ratios.

FINDINGS:
The resulting estimate for the incremental lifetime healthcare cost of the contingency management strategy versus usual care was £22 (95% CI: -£12 to £40) per person offered the incentive. For 1,000 people offered the incentive, the incremental reduction in numbers of hepatitis B infections avoided over their lifetime was estimated at 19 (95% CI: 8 to 30). The probabilistic incremental cost per quality adjusted life year gained of the contingency management programme was estimated to be £6,738 (95% CI: £6,297 to £7,172), with an 89% probability of being considered cost-effective at a threshold of £20,000 per quality-adjusted life years gained (98% at £30,000).

CONCLUSIONS:
Using financial incentives to increase hepatitis B vaccination completion in people who inject drugs could be a cost-effective use of healthcare resources in the UK as long as the incidence remains above 1.2%.

Purchase full article at:   http://goo.gl/smEj2b

  • 1Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield.
  • 2Section of Public Health, School of Health and Related Research (ScHARR), University of Sheffield.
  • 3Injecting Drug Use Team, HIV & STI Department, Centre for Infectious Disease Surveillance and Control, Public Health England (PHE).
  • 4Centre for the Economics of Mental and Physical Health, King's College London.
  • 5National Addiction Centre, Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London.
  • 6Department of Biostatistics, King's College London.
  • 7Department of Mental Health, Social work and Integrative Medicine, Middlesex University. 
  •  2016 Mar 18. doi: 10.1111/add.13385. 



Saturday, February 6, 2016

Improving the Identification of Priority Populations to Increase Hepatitis B Testing Rates, 2012

BACKGROUND:
It is estimated that over 40 % of the 218,000 people with chronic hepatitis B (CHB) in Australia in 2011 are undiagnosed. A disproportionate number of those with undiagnosed infection were born in the Asia-Pacific region. Undiagnosed CHB can lead to ongoing transmission and late diagnosis limits opportunities to prevent progression to hepatocellular carcinoma (HCC) and cirrhosis. Strategies are needed to increase testing for hepatitis B virus (HBV) (including culturally and linguistically diverse communities, Aboriginal and/or Torres Strait Islander (Indigenous) people and people who inject drugs). General practitioners (GPs) have a vital role in increasing HBV testing and the timely diagnosis CHB. This paper describes the impact of a GP-based screening intervention to improve CHB diagnosis among priority populations in Melbourne, Australia.

METHODS:
A non-randomised, pre-post intervention study was conducted between 2012 and 2013 with three general practices in Melbourne, Australia. Using clinic electronic health records three priority populations known to be at increased CHB risk in Australia (1: Asian-born patients or patients of Asian ethnicity living in Australia; 2: Indigenous people; or 3): people with a history of injecting drugs were identified and their HBV status recorded. A random sample were then invited to attend their GP for HBV testing and/or vaccination. Baseline and follow-up electronic data collection identified patients that subsequently had a consultation and HBV screening test and/or vaccination.

RESULTS:
From a total of 33,297 active patients, 2674 (8 %) were identified as a priority population at baseline; 2275 (85.1 %) of these patients had unknown HBV status from which 338 (14.0 %) were randomly sampled. One-fifth (n = 73, 21.6 %) of sampled patients subsequently had a GP consultation during the study period; only four people (5.5 %) were subsequently tested for HBV (CHB detected in n = 1) and none were vaccinated against HBV.

CONCLUSION:
CHB infection is an important long-term health issue in Australia and strategies to increase appropriate and timely testing are required. The study was effective at identifying whether Asian-born patients and patients of Asian had been tested or vaccinated for HBV; however the intervention was not effective at increasing HBV testing.

Full article at:  http://goo.gl/ADG29j

By:  van Gemert C1,2Wang J3Simmons J4Cowie B5,6Boyle D7Stoove M3,8Enright C4Hellard M3,8.
  • 1Centre for Population Health, Burnet Institute, Melbourne, Australia. carolinevg@burnet.edu.au.
  • 2Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia. carolinevg@burnet.edu.au.
  • 3Centre for Population Health, Burnet Institute, Melbourne, Australia.
  • 4Cancer Council Victoria, Melbourne, Australia.
  • 5WHO Collaborating Centre for Viral Hepatitis, Doherty Institute, Melbourne, Australia.
  • 6Department of Medicine, University of Melbourne, Melbourne, Australia.
  • 7GRHANITE™ Health Informatics Unit, Health and Biomedical Informatics Centre, University of Melbourne, Melbourne, Australia.
  • 8Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia. 
  •  2016 Feb 1;16(1):95. doi: 10.1186/s12889-016-2716-7.



Wednesday, December 30, 2015

Hepatitis B Virus Status in Children Born to HIV/HBV Coinfected Women in a French Hospital

OBJECTIVES:
We assessed hepatitis B virus (HBV) status in children born to HIV/HBV coinfected women with large access to antiretroviral therapy.

METHODS:
All HIV/HBV coinfected pregnant women from 01 January 2000 to 01 January 2012 were included in the retrospective study (NCT02044068). Antiretroviral therapy during pregnancy and injection of HBV immunoglobulin/vaccine to newborns was recorded. We assessed HBV status of children aged at least 2 years.

RESULTS:
Twenty-one women (35 children) were studied. Twenty-six children (74%) had HBsAb: 22 had received immunoglobulin and 24 had received a complete vaccine (with immunoglobulin in 21 cases); their mothers had been administered lamivudine or tenofovir/emtricitabine during eight and nine pregnancies, respectively. Eight children (23%) were negative for HBsAg, HBsAb, and HBcAb: four (11.5%) had received immunoglobulin and a complete vaccine; in two children, it was not known whether they had received an immunoglobulin injection; in one child, the vaccine was incomplete; and in the last one, it was not known whether he had received immunoglobulin/vaccine. Their mothers had been administered lamivudine or tenofovir/emtricitabine during five and two pregnancies, respectively. No infant has chronic HBV infection (HBsAg) after prenatal mothers' antiretroviral therapy combined with a complete postnatal HBV protection. One child had HBcAb and HBsAb: it was not known whether she had received an immunoglobulin injection; the vaccine was incomplete. The mother had been administered lamivudine during the last trimester of pregnancy.

CONCLUSION:
Antiretroviral therapy in HBV/HIV coinfected women following current national HBV guidelines may prevent mother-to-child-transmission of HBV. Negativity of surrogate markers of vaccine-induced protection is frequent; large studies on long-term protection are needed.

Purchase full article at:   http://goo.gl/NUeRCW

1aDepartment of Internal Medicine A bDepartment of Virology cDepartment of Microbiology dDepartment of Obstetrics ePharmacy, AP-HP, Saint-Louis-Lariboisière Hospital fInfectious Diseases Department, AP-HP, Bichat - Claude Bernard Hospital, HUPNVS; Paris-Diderot, Sorbonne Paris-Cité University, Paris, France.




Friday, December 25, 2015

Development of Immunity Following Financial Incentives for Hepatitis B Vaccination among People Who Inject Drugs

BACKGROUND:
People who inject drugs (PWID) are at risk of hepatitis B virus (HBV) but have low rates of vaccination completion. The provision of modest financial incentives increases vaccination schedule completion, but their association with serological protection has yet to be determined.

OBJECTIVE:
To investigate factors associated with vaccine-induced immunity among a sample of PWID randomly allocated to receive AUD$30 cash following receipt of doses two and three ('incentive condition') or standard care ('control condition') using an accelerated 3-dose (0,7,21 days) HBV vaccination schedule.

STUDY DESIGN:
A randomised controlled trial among PWID attending two inner-city health services and a field site in Sydney, Australia, assessing vaccine-induced immunity measured by hepatitis B surface antibodies (HBsAb≥10mIU/ml) at 12 weeks. The cost of the financial incentives and the provision of the vaccine program are also reported.

RESULTS:
Just over three-quarters of participants - 107/139 (77%) - completed the vaccination schedule and 79/139 (57%) were HBsAb≥10mIU/ml at 12 weeks. Vaccine series completion was the only variable significantly associated with vaccine-induced immunity in univariate analysis (62% vs 41%, p<0.035) but was not significant in multivariate analysis. There was no statistically discernible association between group allocation and series completion (62% vs 53%). The mean costs were AUD$150.5, (95% confidence interval [CI]: 142.7-158.3) and AUD$76.9 (95% CI: 72.6-81.3) for the intervention and control groups respectively.

CONCLUSION:
Despite increasing HBV vaccination completion, provision of financial incentives was not associated with enhanced serological protection. Further research into factors which affect response rates and the optimal vaccination regimen and incentive schemes for this population are needed.

Purchase full article at:   http://goo.gl/bV46jx

  • 1Discipline of Addiction Medicine, Central Clinical School (C39), Sydney Medical School, University of Sydney, NSW 2006, Australia. Electronic address: carolyn.day@sydney.edu.au.
  • 2National Drug and Alcohol Research Centre, University of New South Wales, NSW 2052, Australia.
  • 3The Kirby Institute, UNSW Australia, Sydney, NSW 2052, Australia.
  • 4Cancer Council NSW, Woolloomooloo, NSW 2010, Australia.
  • 5Discipline of Addiction Medicine, Central Clinical School (C39), Sydney Medical School, University of Sydney, NSW 2006, Australia; Drug Health Services, Royal Prince Alfred Hospital, Missenden Road, Camperdown,NSW 2050, Australia.
  • 6Kirketon Road Centre, South Eastern Sydney Local Health District, Kings Cross, NSW 1340 Australia.
  • 7Discipline of Addiction Medicine, Central Clinical School (C39), Sydney Medical School, University of Sydney, NSW 2006, Australia.
  • 8Department of Epidemiology and Preventive Medicine, Monash University, 89 Commercial Road, Melbourne, Victoria 3004, Australia. 


Tuesday, December 22, 2015

Hepatitis B Vaccination Uptake & Correlates of Serologic Response among HIV-Infected & Uninfected Men Who Have Sex with Men (MSM) in Bangkok, Thailand

BACKGROUND:
Vaccination against hepatitis B virus (HBV) is recommended for all HBV-susceptible men who have sex with men (MSM). There is limited information on correlates of immunity to HBV vaccination in this group. We present serologic response rates to hepatitis B vaccine and identify factors associated with impaired response among HIV-uninfected and HIV-infected Thai MSM.

METHODOLOGY:
HBV-susceptible volunteers were offered hepatitis B vaccination at months zero, one, and six. We measured baseline (pre-vaccination) total serum IgG and IgG subclasses (all participants), baseline CD4 count, and plasma HIV-1 viral load (PVL) (HIV+ participants). HBV serologies were retested at 12 months. Serologic responses were compared between all groups in men receiving three vaccine doses.

RESULTS:
511/651 HIV-negative and 64/84 HIV-positive participants completed the three-dose series. Response rates in HIV-uninfected and -infected participants were 90.1% vs. 50.0% (p<0.0001). Median pre-vaccination IgG was higher among non-responders than responders overall (1238.9.0 vs. 1057.0mg/dL, p=0.003) and among HIV-infected participants (1534.0 vs. 1244.5mg/dL, p=0.005), but not significantly among HIV-uninfected participants (1105.5 vs. 1054.3mg/dL, p=0.96). Pre-vaccination IgG1 and IgG3 levels were higher among HIV-positive than HIV-negative participants (median 866.0 vs. 520.3, and 105.8 vs. 83.1mg/dL, respectively, p<0.0001). Among HIV-infected participants, median CD4 count in non-responders was 378 cells/μL vs. 431 cells/μL in responders (p=0.20). Median PVL in non-responders was 64,800 copies/mL vs. 15500 copies/mL in responders (p=0.04). Participants with pre-vaccination plasma IgG >1550mg/dL and PVL >10,000 copies/mL were almost always non-responsive (p<0.01).

CONCLUSIONS:
HIV infection was associated with poor vaccine responses. High plasma viral load, elevated pre-vaccination total serum IgG and elevated pre-vaccination IgG1 are associated with poorer response to vaccination among HIV-infected MSM. In this group, the combination of high PVL and pre-vaccination total IgG is highly predictive of vaccine failure.

Purchase full article at:   http://goo.gl/O9flQo

  • 1Thailand Ministry of Public Health-U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand.
  • 2Thailand Ministry of Public Health-U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand; Division of HIV/AIDS Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • 3Division of HIV/AIDS Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • 4Thailand Ministry of Public Health-U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand; Thai Red Cross Society AIDS Research Center, Bangkok, Thailand.
  • 5Thailand Ministry of Public Health-U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand; Division of HIV/AIDS Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: vdu7@th.cdc.gov. 


Monday, December 21, 2015

Population-Based Multicentric Survey of Hepatitis B Infection and Risk Factors in the North, South, and Southeast Regions of Brazil, 10–20 Years after the Beginning of Vaccination

A population-based hepatitis survey was carried out to estimate the prevalence of hepatitis B virus (HBV) infection and its predictive factors for the state capitals from the north, south, and southeast regions of Brazil. 

A multistage cluster sampling was used to select, successively, census tracts, blocks, households, and residents in the age group 10–69 years in each state capital. The prevalence of hepatitis B surface antigen (HBsAg) was lower than 1% in the north, southeast, and south regions. Socioeconomic condition was associated with HBV infection in north and south regions. Variables related to the blood route transmission were associated with HBV infection only in the south whereas those related to sexual behavior were associated with HBV infection in the north and south regions. Drug use was associated in all regions, but the type of drug differed. 

The findings presented herein highlight the diversity of the potential transmission routes for hepatitis B transmission in Brazil. In one hand, it reinforces the importance of national control strategies of large impact already in course (immunization of infants, adolescents, and adults up to 49 years of age and blood supply screening). On the other hand, it shows that there is still room for further control measures targeted to different groups within each region.

Below: Distribution of population aged 13–69 years in the state capitals of the North, South and Southeast Regions of Brazil and of the census tracts, households and individuals sampled.




Table 6

Factors associated with hepatitis B infection in three regions of Brazil, 2005
CharacteristicsNorthSoutheastSouth
OR (95% CI)*P valueOR (95% CI)P valueOR (95% CI)P value
Sex
 Female1.0
 Male1.49 (1.02–2.19)0.041
Age (in years)1.05 (1.03–1.06)0.0001.06 (1.05–1.08)0.0001.04 (1.03–1.05)0.000
Read and write
 Yes1.0
 No3.14 (1.53–6.46)0.002
Schooling
 Illiterate1.0
 Basic level0.78 (0.53–1.15)0.214
 2nd level & univ0.51 (0.32–0.81)0.004
Paid work past week
 Yes1.0
 No0.56 (0.40–0.76)0.000
Sewage disposal
 Pubic system1.01.0
 Septic tanks0.61 (0.40–0.93)0.0211.71 (1.28–2.29)0.000
 Other destination0.83 (0.40–1.72)0.617
Blood transfusion
 Never1.0
 Past 12 months2.28 (1.11–4.67)0.024
 Ever0.68 (0.41–1.15)0.152
Endoscopy
 Never1.0
 Past 12 months1.27 (0.80–2.05)0.311
 Ever1.33 (0.99–1.80)0.059
Share toothbrush
 No1.0
 Yes1.81 (1.05–3.12)0.032
Condom use
 Not started sex life1.0
 Yes, regularly2.41 (0.96–6.06)0.060
 Yes, sometimes3.68 (1.65–8.22)0.001
 Never3.90 (1.54–9.88)0.004
Bisexual partner
 Not started sex life1.0
 No2.37 (0.87–6.42)0.089
 Yes1.68 (1.17–2.41)0.005
Ever used smoked drugs
 No1.0
 Yes1.58 (1.05–2.36)0.026
Ever used inhaled drugs
 No1.0
 Yes3.85 (1.19–12.4)0.024
Ever sniffed drugs
 No1.0
 Yes1.73 (1.01–2.97)0.048
Ever injecting drugs
 No1.0
 Yes2.49 (0.82–7.54)0.106
Classification elitism
 Abstemious
 Light drinker0.95 (0.63–1.44)0.815
 Heavy drinker1.96 (1.06–3.59)0.030
CI = confidence interval; OR = odds ratio.

Full article at:   http://goo.gl/KfU31K

Hospital Universitário Oswaldo Cruz, Faculdade de Ciências Médicas de Pernambuco, Universidade de Pernambuco, Pernambuco, Brazil; Departamento de Medicina Tropical, Universidade Federal de Pernambuco, Cidade Universitária, Pernambuco, Brazil; Instituto de Medicina Tropical da Universidade de São Paulo, São Paulo, Brazil; Departamento de Epidemiologia, Faculdade de Saúde Pública, Universidade de São Paulo, São Paulo, Brazil; Fundação Universidade Federal de Ciências da Saúde de Porto Alegre, Rio Grande do Sul, Brazil; Instituto Adolfo Lutz, São Paulo, Brazil; Secretaria de Saúde Pública do Estado do Pará, Pará, Brazil; Instituto Bioestatístico, Pará, Brazil; Instituto de Ciências Biológicas, Universidade de Pernambuco, Pernambuco, Brazil; Fundação Oswaldo Cruz, Centro de Pesquisas Aggeu Magalhães, Cidade Universitária, Pernambuco, Brazil; Instituto do Fígado de Pernambuco, Pernambuco, Brazil
*Address correspondence to Ricardo A. A. Ximenes, Faculdade de Ciências Médicas de Pernambuco, Hospital Universitário Oswaldo Cruz, Universidade de Pernambuco, Rua Arnóbio Marques, 310, Santo Amaro, CEP 50100-130, Recife, Pernambuco, Brazil. E-mail:rb.moc.lou@senemixaar